Source notes
Source checks are dated individually below. Earlier material retains its original source history. Provider pages document advertised terms. Study summaries identify the scope of our review.
- FDA — creating and keeping a medication listPatient safety and medication records
- FDA — safely using sharps at home, work and while travelingSharps disposal safety
- NIA — questions for a medical checkupPatient communication
- NIA — talking with your doctor worksheetsAppointment preparation tools
- FDA — prescription medicine labeling FAQProduct document context
- FDA — compounding questions and answersRegulatory context
- FDA — unapproved GLP-1 drug concernsSafety information · Checked 2026-10-21
- CoreAge Rx — semaglutide offerProvider page
- CoreAge Rx — tirzepatide offerProvider page
- CoreAge Rx — pricing and plansProvider terms
- SuperHealthy Rx — current GLP-1 promotionProvider offer
- Likeness Rx — GLP-1 plan informationProvider offer and billing terms
- Ro — Body program and pricingProvider membership
- Noom Med — program pricingProvider offer; branded pathway reviewed
- Noom — branded-medication prescriptionsProvider pharmacy and follow-up process
- Found — plan offer termsProvider contract; branded plan reviewed
- It can be a lifesaving tool, especially during an emergencyPrimary health resource; checked October 5, 2026
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight LossPrimary health resource; checked October 5, 2026
- FAQs | HersProvider public offer; checked October 5, 2026
- Frequently Asked Questions | LifeMD®Provider public offer; checked October 5, 2026
- Safely Using Sharps (Needles and Syringes)Federal patient information; checked October 5, 2026
- What Should I Ask My Doctor During a Checkup?Primary health resource; checked October 5, 2026
- Choosing a Safe & Successful Weight-loss Program - NIDDKPrimary health resource; checked October 5, 2026
- Weight Loss Care for Women, Built to Last | HersProvider public offer; checked October 5, 2026
- Online weight loss medication with or without insuranceProvider public offer; checked October 5, 2026
- Calibrate Weight Loss Pricing: How Much Does Calibrate Cost? | CalibrateProvider public offer; checked October 5, 2026
- Weight Management Program Overview | LifeMD®Provider public offer; checked October 5, 2026
- Programs & Membership Plans | LifeMD®️Provider public offer; checked October 5, 2026
- Bare Lúx Studio: Medical weight-loss serviceProvider public information; checked October 15, 2026
- Bare Lúx Studio: Consultation deposit and practice overviewProvider public information; checked October 15, 2026
- Bare Lúx Studio: Team and older booking FAQProvider public information; checked October 15, 2026
- Bare Lúx Studio: Booking, payment and refund terms; April 29, 2026Provider public information; checked October 15, 2026
- FDA: Concerns with unapproved GLP-1 drugs used for weight lossMedication safety context; checked October 15, 2026
- Pacific Northwest Medical Group: Submitted voucher landing pageProvider public information; checked October 15, 2026
- PNW voucher page: Linked privacy and website termsProvider public information; checked October 15, 2026
- Pacific Northwest Medical Group: Current clinic overviewProvider public information; checked October 15, 2026
- PNW Medical Group: October 2026 pricing and autopay conditionsProvider public information; checked October 15, 2026
- PNW Medical Group: Medication and follow-up programProvider public information; checked October 15, 2026
- PNW Medical Group: Puyallup and Federal Way clinicsProvider public information; checked October 15, 2026
- Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.Indexed original research abstract · Checked 2026-10-21
- FDA approves treatment for serious liver disease known as MASHOfficial FDA page read through web tool; historical approval announcement, not complete current labeling · Checked 2026-10-21
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.Primary research or official information · Checked 2026-10-21
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.Primary research or official information · Checked 2026-10-21
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.Indexed original research abstract · Checked 2026-10-21
- Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.Indexed original research abstract · Checked 2026-10-21
- DailyMed - FOUNDAYO- orforglipron tablet, film coatedOfficial page retrieved in full · Checked 2026-10-21
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.Primary research or official information · Checked 2026-10-21
- Sesame GLP-1 programProvider description · Checked 2026-11-20